Global Trial Accelerators™

🧬 Cellular reprogramming hits human trials milestone

Why Latin America Continues to Lead Early-Phase Clinical Trial Execution

Can your study survive Brazil’s import maze? 🇧🇷

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below. The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Necessary cookies are required to enable the basic features of this site, such

Brazil’s Clinical Trial Import Maze — Simplified

🧪 Fast-track trials in Mexico? See what’s changing

PUBLICADO: enero 19, 2026 | 10:42 am México fortalece la investigación clínica con acciones para implementar la NOM-262-SSA1-2024, un piloto para autorizar protocolos prioritarios en hasta 45 días y mayor revisión de consentimiento informado y comités de ética. En el marco del Plan México, la Secretaría de Salud (SS), La agenda presentada por las autoridades sanitarias se enfocó en consolidar u

Strengthened Oversight & Faster Timelines in Mexico

📊 AI is speeding up trial insights—here’s how

The FDA has announced new regulatory flexibilities specifically designed for cell and gene therapies, moving away from one-size-fits-all manufacturing requirements. These changes acknowledge that cell and gene therapies require different approaches than traditional drugs due to their complexity and individualized nature.

Key Points:

• CBER will apply tailored chemistry, manufacturing, and control requirements rather than standard expectations across all products
• Sponsors can expect more accommodating approaches for sophisticated manufacturing processes and time-sensitive production constraints
• Previously case-by-case flexibilities will now be communicated broadly to expedite development across the entire CGT field
• All sponsor teams will receive consistent guidance on scientifically acceptable regulatory flexibility options regardless of reviewer assignment
• Safety, purity, and potency standards remain rigorous while removing barriers that slow product development timelines

Why It Matters: These regulatory changes create clearer pathways for bringing innovative cell and gene therapies to market faster while maintaining the safety standards patients depend on.

FDA Clears the Way for Faster Cell & Gene Therapy Trials

🔬 Retro Bio Begins First-in-Human Longevity Study

Eastern Europe has emerged as a strategic solution for accelerating clinical trial timelines and reducing costs. The region's streamlined regulatory processes and experienced professionals are transforming how medical device companies approach early-stage studies.

Key Points:

• Regulatory pathways in Eastern Europe deliver faster approval times compared to traditional markets
• Cost structures in the region provide significant budget advantages for early feasibility studies
• Local clinical research professionals bring specialized expertise to complex trial designs
• Infrastructure supports efficient patient recruitment and study execution timelines
• Recent case studies demonstrate measurable improvements in time-to-market for medical innovations

Why It Matters: Faster regulatory approval translates directly to reduced development costs and earlier market entry for your medical device innovations.

Eastern Europe’s Role in Accelerating Clinical Trials

🧬 Could FDA updates speed your early-phase trial?

RevBio's TETRANITE biomaterial has entered clinical trials for dental ridge augmentation procedures, marking a significant expansion of the product's approved indications. This adhesive bone scaffold technology addresses critical challenges in dental implant procedures where traditional bone graft materials frequently fail to deliver adequate results.

Key Points:

• TETRANITE adheres directly to surrounding bone walls without requiring additional fixation or containment devices
• The biomaterial prevents soft tissue ingrowth while maintaining structural integrity throughout the healing process
• New bone formation occurs within clinically relevant timeframes while preserving the original implantation volume
• Traditional particulate bone grafts fail in over 30% of cases, requiring costly and time-intensive repeat procedures
• The technology received $1.8 million in funding from the National Institute of Dental and Cranial Research

Why It Matters: This clinical trial represents a pathway to reducing the 30% failure rate of current bone grafting procedures while eliminating the need for complex containment devices in dental reconstruction.

RevBio Gains FDA Green Light for Regenerative Bone Glue Trial

🌐 LATAM’s growing role in early-phase trials

Clinical trial websites implement comprehensive cookie frameworks to manage user data collection and maintain regulatory compliance across multiple jurisdictions. These systems categorize cookies into necessary, functional, analytical, performance, and advertisement types, each serving specific operational requirements for research platforms.

Key Points:

• Necessary cookies maintain essential site functions including secure authentication and consent preference management
• Analytical cookies track user behavior patterns and site performance metrics through Google Analytics and HubSpot integration
• Functional cookies enable social media integration and third-party platform connectivity for research collaboration
• Advertisement cookies facilitate targeted content delivery and campaign effectiveness measurement via DoubleClick systems
• Performance cookies monitor website speed and user experience optimization across clinical trial management platforms

Why It Matters: Proper cookie management ensures regulatory compliance while maintaining seamless user experiences for clinical research professionals navigating complex trial management platforms.

Australia Opens the Door to Faster Approvals

🧬 What’s New in Gene Therapy? FDA Approves a First

The FDA has approved Waskyra, the first gene therapy treatment for Wiskott-Aldrich syndrome, marking a significant regulatory precedent for rare disease therapeutics. This approval demonstrates how regulatory agencies are adapting their frameworks to accelerate access to life-saving treatments for underserved patient populations.

Key Points:

• Waskyra uses patients' own genetically modified hematopoietic stem cells to treat the underlying genetic cause of Wiskott-Aldrich syndrome
• Clinical studies showed 93% reduction in severe infections and 60% reduction in bleeding events within the first year post-treatment
• FDA exercised regulatory flexibility across trial design, manufacturing controls, and data requirements to expedite approval for this rare disease
• Approval was based on data from two open-label studies and expanded access programs involving 27 patients with severe disease
• Fondazione Telethon ETS becomes the first non-profit organization to receive FDA approval for a cell and gene therapy product

Why It Matters: This approval establishes a regulatory pathway that could accelerate development timelines and reduce barriers for innovative therapies targeting rare diseases with limited treatment options.

FDA Approves First Gene Therapy Treatment for Wiskott-Aldrich Syndrome

🇷🇸 Serbia fast-tracks early-phase trial approvals

Serbia's regulatory framework for vaccine trials has evolved significantly since the early 19th century, with the Medicines and Medical Devices Agency of Serbia (ALIMS) now serving as the primary oversight body. This streamlined system offers efficient pathways for clinical research while maintaining rigorous safety and ethical standards.

Key Points:

• ALIMS completes regulatory assessments within 60 days while local ethics committees typically provide approvals within 30 days
• Serbia has approved 452 clinical studies since 2023, demonstrating an active and supportive regulatory environment
• The 2010 Law on Medicines and Medical Devices aligned Serbian standards with European Union requirements
• Local representatives can serve as regulatory proxies to facilitate communication with ALIMS throughout the approval process
• Recent streamlining efforts have reduced some study approvals to as little as three weeks for qualifying protocols

Why It Matters: Serbia's efficient regulatory framework and EU-aligned standards provide medtech companies with faster market access while maintaining the rigorous oversight required for successful vaccine development programs.

Serbia Steps Up: A Smoother Route for Vaccine and Early-Phase Trials

🧬 First-in-human gene therapy shows early promise

Modern websites deploy sophisticated cookie tracking systems that monitor user behavior, store preferences, and enable personalized experiences. These digital identifiers serve multiple functions across security, analytics, marketing, and operational requirements.

Key Points:

• Necessary cookies maintain essential site functions including secure login authentication and fraud prevention protocols
• Functional cookies enable social media integration, video preferences, and third-party service connectivity
• Analytical cookies track visitor patterns, session data, and site performance metrics for optimization purposes
• Performance cookies regulate data collection rates and manage system resources on high-traffic platforms
• Advertisement cookies deliver targeted content based on browsing history and measure campaign effectiveness

Why It Matters: Understanding cookie categories helps organizations implement compliant data collection strategies while maintaining operational efficiency and user experience standards.

Scaling Medtech Trials in Latin America with Precision and Speed